There’s a great opportunity for Australian SME’s to take advantage of a well-deserved subsidy!
Agilex Biolabs is thrilled to partner with Therapeutic Innovation Australia (TIA) through the Pipeline Accelerator Scheme, providing Australian researchers, SMEs and Biotechnology companies with a unique opportunity to unlock subsidies for preclinical development. This scheme enables access to cutting-edge and experienced preclinical toxicology services that are essential for advancing therapeutic research, all for a saving of up to $50,000. If you’re currently considering your budgets for 2025, this is an unprecedented opportunity to extend your cash runway and generate critical data to boost your development activities forward.
What the Pipeline Accelerator Offers
The TIA Pipeline Accelerator Scheme, supported by the National Collaborative Research Infrastructure Strategy (NCRIS), aims to lower the financial barrier in early drug development and access specific capabilities from approved facilities, of which Agilex is uniquely positioned to help you maximise the benefits. In a nutshell, this voucher-based scheme funds up to $50,000 of critical therapeutic development work and requires at least 50% co-investment (matching funding) from you.
How can Agilex help?
Agilex plays a pivotal role in this scheme by offering pre-GLP toxicology studies tailored to accelerate your therapeutic programs efficiently. Our services within the scheme focus on key early-stage discovery and non-clinical studies that provide the foundation for clinical trial applications:
- Pharmacokinetics (PK) Studies: Gain insights into the absorption, distribution, metabolism, and excretion (ADME) of your compound, with blood sample collection and analysis support.
- Maximum Tolerated Dose (MTD) Studies: Identify the highest dose of your compound that can be administered without unacceptable toxicity, a critical milestone for progressing to formal GLP studies.
- Dose Range Finding (DRF) Studies: Establish safe and effective dosing regimens to inform subsequent preclinical and clinical studies.
Why work with Agilex?
The Agilex team has over 80 years of combined expertise in preclinical toxicology including submission of GLP data to global regulators (FDA, EMA, TGA etc.), meaning that you will be working with scientists who understand what it takes to progress to the clinic and what development pathways will get you there efficiently. We have the capability to perform studies in standard and non-standard animal strains, and have supported development across various therapeutic modalities and new chemical entities. Our core offering enables our clients to proceed to the more formal preclinical studies to support clinical trial application.
By partnering with us, you’ll not only access our world-class preclinical toxicology capabilities, but also benefit from:
- Expert guidance: We will collaborate closely with you to design studies that will answer your scientific questions.
- More data, less spend: This scheme enables you to conduct studies that generates in vivo data, all at 50% of the cost!
- A critical step towards more funding: These studies are the fundamental steppingstones towards clinical trials. By generating early proof-of-concept and safety data in animals, you gain more leverage in attracting investor interest to fund your program beyond this scheme.
How to get started
To qualify for the Pipeline Accelerator Scheme, applicants must obtain quotes from Agilex on the required services, outline their proposed project, and demonstrate the project’s potential to advance therapeutic development. The team at Agilex will work with you to step through the eligibility criteria, provide the necessary service quotes and project support to help secure the subsidy. As a first step, get in touch with us at bd@agilexbiolabs.com to organise a call and discuss how we can partner on this scheme together. There are limited funds, so don’t miss your chance to access up to $50,000 on your journey of transforming groundbreaking ideas into life-changing therapies!
